Business Context and Reporting Period
This Form 8-K Current Report was filed by Quince Therapeutics, Inc. (QNCX) on April 22, 2026. The report discloses a corporate governance event: the appointment of a new independent director to the Board of Directors.
Key Financial Metrics
The filing text does not provide a clear value for revenue, profit, cash flow, margins, debt, or liquidity. This report focuses exclusively on board composition and director compensation.
Material Changes
The Board of Directors increased the number of directors to four and appointed June Bray as a Class I director, effective immediately. Ms. Bray was appointed to serve until the 2026 Annual Meeting of Stockholders or until earlier death, disqualification, resignation, or removal. She has been designated as an independent director under Nasdaq listing standards and appointed to the Nominating & Governance, Audit, and Compensation Committees.
Guidance, Outlook, and Compensation Details
There is no guidance, outlook, or management commentary regarding business operations or risks in this filing. Regarding compensatory arrangements, Ms. Bray will receive standard non-employee director compensation but will not receive an option grant in connection with her appointment. Her compensation package includes:
- Board Retainer: $38,000 annually.
- Nominating & Governance Committee: $7,500 annually.
- Audit Committee: $5,500 annually.
- Compensation Committee: $4,000 annually.
Ms. Bray will also enter into the Company's standard form of indemnification agreement.
Investor Verification Checklist
- Verify the total annual cash compensation for Ms. Bray ($55,000) against the Company's Outside Director Compensation Policy filed as Exhibit 10.14 to the April 10, 2026 Form 10-K.
- Confirm the independence status of Ms. Bray under Nasdaq listing standards.
- Review the standard indemnification agreement (Exhibit 10.4 to the April 10, 2026 Form 10-K) to understand liability protections.
- Note that no equity options were granted for this appointment, which may differ from standard practices for new directors.